Search results for "Colectomy"

showing 10 items of 80 documents

Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.

2019

AIMS It is recommended that tumour budding in colon cancer be counted on haematoxylin and eosin-stained sections in a hotspot area of 0.785 mm2 with a ×20 microscope objective. However, tumour buds may be difficult to visualise on haematoxylin and eosin-stained sections, and counting in such a limited area may result in overestimation in cases with focal budding. The aim of this study was to assess the contributions of various factors to improving tumour budding risk stratification: increasing the number of fields counted, using cytokeratin immunostaining, and recording proliferation, the apoptotic index and the emperipoletic index in tumour buds. METHODS AND RESULTS We created an explorato…

0301 basic medicineAdultMalePathologymedicine.medical_specialtyHistologyMitotic indexColorectal cancermedicine.medical_treatmentKaplan-Meier EstimateDisease-Free SurvivalPathology and Forensic Medicine03 medical and health sciencesCytokeratin0302 clinical medicineTumor buddingMedicineHumansGrading (tumors)ColectomyColectomyAgedAged 80 and overPathology Clinicalbusiness.industryHazard ratioGeneral MedicineMiddle Agedmedicine.disease030104 developmental biology030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm GradingbusinessImmunostainingHistopathologyReferences
researchProduct

Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database r…

2021

Purpose: This study aimed to report the uptake of hysterectomy and/or bilateral salpingo-oophorectomy (BSO) to prevent gynaecological cancers (risk-reducing surgery [RRS]) in carriers of pathogenic MMR (path_MMR) variants.Methods: The Prospective Lynch Syndrome Database (PLSD) was used to investigate RRS by a cross-sectional study in 2292 female path_MMR carriers aged 30-69 years.Results: Overall, 144, 79, and 517 carriers underwent risk-reducing hysterectomy, BSO, or both combined, respectively. Two-thirds of procedures before 50 years of age were combined hysterectomy and BSO, and 81% of all procedures included BSO. Risk-reducing hysterectomy was performed before age 50 years in 28%, 25%,…

0301 basic medicineCancer ResearchOophorectomyDatabases FactualColorectal cancerSURGERYmedicine.medical_treatmentCàncer d'ovaricomputer.software_genreDNA Mismatch Repair0302 clinical medicineEndometrial cancermunasarjasyöpäMedicineProspective StudiesColectomySalpingo-oophorectomy/methodsDatabaseManchester Cancer Research CentreCOLON-CANCERMLH1WOMENMiddle AgedPrognosisLynch syndrome3. Good healthkohdunrungon syöpäOncologyCOLECTOMY030220 oncology & carcinogenesisFemaleBiomarkers Tumor/geneticsAdultHeterozygoteGenital Neoplasms FemaleSalpingo-oophorectomyHysterectomy03 medical and health sciencesGenital Neoplasms Female/prevention & controlOvarian cancerColorectal Neoplasms Hereditary Nonpolyposis/geneticsBiomarkers TumorMortalitatHumansHysterectomy/methodsMortalityLynchin oireyhtymäRisk-reducing surgeryAgedHysterectomybusiness.industryEndometrial cancerResearchInstitutes_Networks_Beacons/mcrcCancerOophorectomyMSH63126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisMSH2030104 developmental biologyCross-Sectional StudiesLynch syndromePMS2Càncer d'endometriMutationkohdunpoistobusinessOvarian cancercomputerFollow-Up Studies
researchProduct

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

2019

Objective. To determine pre-/intraoperative risk factors for anastomotic leak after modified posterior pelvic exenteration (MPE) or colorectal resection in ovarian cancer and to create a practical instrument for predicting anastomotic leak risk. Background. In advanced ovarian cancer surgery, there is rather limited published evidence, drawn from a small sample, providing information about risk factors for anastomotic leak. Methods. Eight hospitals participated in this retrospective study. Data on 695 patients operated for ovarian cancer with primary anastomosis were included (January 2010-June 2018). Twelve pre-/intraoperative variables were analysed as potential independent risk factors f…

0301 basic medicineLeakmedicine.medical_specialtyMultivariate analysisAnastomotic LeakAnastomosisStoma03 medical and health sciences0302 clinical medicineOvarian cancerRetrospective StudieRisk FactorsIntestine SmallmedicineAnastomotic leakHumansAge FactorColectomySerum AlbuminAgedRetrospective StudiesOvarian NeoplasmsProctectomybusiness.industryIncidence (epidemiology)Ovarian NeoplasmRisk FactorAnastomosis SurgicalSuture TechniquesAge FactorsObstetrics and GynecologyRetrospective cohort studyMiddle Agedmedicine.diseasePosterior Pelvic ExenterationSurgeryPelvic Exenteration030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalOvarian cancerbusinessHumanGynecologic oncology
researchProduct

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

2019

A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool to better detect risk of relapse.One hundred and fifty patients diagnosed with localized CC were prospectively enrolled in our study. Tumor tissue from those patients was sequenced by a custom-targeted next-generation sequencing (NGS) panel to characterize somatic mutations. A minimum varian…

0301 basic medicineOncologyMalemedicine.medical_specialtyNeoplasm ResidualColorectal cancerColonmedicine.medical_treatmentPathological stagingConcordanceDNA Mutational AnalysisKaplan-Meier EstimateAdenocarcinomaDisease-Free Survivallaw.inventionCirculating Tumor DNA03 medical and health sciences0302 clinical medicineGene FrequencylawInternal medicineBiomarkers TumorMedicineHumansDigital polymerase chain reactionPostoperative PeriodProspective StudiesPolymerase chain reactionColectomyAgedChemotherapybusiness.industryHazard ratioHigh-Throughput Nucleotide SequencingHematologymedicine.diseaseMinimal residual disease030104 developmental biologyOncology030220 oncology & carcinogenesisColonic NeoplasmsMutationFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

CLINICAL COURSE OF SEVERE COLITIS: A COMPARISON BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS.

2018

Few data are available about the clinical course of severe colonic Crohn’s disease (CD). The aim of this study is to describe the clinical course of severe Crohn’s colitis in a patient cohort with isolated colonic or ileocolonic CD, and to compare it with the clinical course of patients with severe ulcerative colitis (UC). Thirty-four patients with severe Crohn’s colitis were prospectively identified in our cohort of 593 consecutive hospitalized patients through evaluation of the Crohn’s Disease Activity Index score and the Harvey-Bradshaw Index. One hundred sixty-nine patients with severe ulcerative colitis were prospectively identified in our cohort of 449 consecutive hospitalized patient…

AdultMaleSettore MED/18 - Chirurgia GeneraleSettore MED/12 - GastroenterologiaCrohn DiseaseHumansColitis UlcerativeFemalecolectomy Crohn's diesease ulcerative colitisMiddle Aged
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Contrast-enhanced ultrasonography: usefulness in the assessment of postoperative recurrence of Crohn's disease.

2013

Abstract Aim The aim of this study was to assess whether the contrast-enhanced ultrasonography (CEUS) can increase the value of the ultrasonography in the study of postoperative recurrence of Crohn's disease (CD). Materials and methods 60 patients with CD who had previously undergone ileocolic resection underwent prospectively both CEUS and colonoscopy within a 3-day period. The sonographic examination included evaluation of bowel wall thickness, transmural complications, colour Doppler grade and contrast-enhanced US. In addition a sonographic score was established. The capacity of CEUS to diagnose endoscopic recurrence, as well as its severity, was assessed by calculating the sensitivity, …

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentFistulaSulfur HexafluorideColonoscopyContrast MediaDoppler echocardiographySensitivity and SpecificitySeverity of Illness IndexYoung AdultCrohn DiseaseIleumRecurrencePositive predicative valuemedicineHumansProspective StudiesUltrasonography Doppler ColorColectomyPhospholipidsColectomyReceiver operating characteristicmedicine.diagnostic_testbusiness.industryGastroenterologyGeneral MedicineColonoscopyMiddle Agedmedicine.diseaseEndoscopyTreatment OutcomeFemaleRadiologybusinessContrast-enhanced ultrasoundFollow-Up StudiesJournal of Crohn'scolitis
researchProduct

Anastomotic leakage after colon cancer resection: does the individual surgeon matter?

2016

Aim Anastomotic leakage is one of the most feared complications after colonic resection. Many risk factors for anastomotic leakage have been reported, but the impact of an individual surgeon as a risk factor has scarcely been reported. The aim of this study was to assess if the individual surgeon is an independent risk factor for anastomotic leakage in colonic cancer surgery. Method This was a retrospective analysis of prospectively collected data from patients who underwent elective resection for colon cancer with anastomosis at a specialized colorectal unit from January 1993 to December 2010. Anastomotic leaks were diagnosed according to standardized criteria. Patient and tumour character…

AdultMalemedicine.medical_specialtyBlood transfusionindividual surgeonColonColorectal cancermedicine.medical_treatmentAnastomotic Leak030230 surgeryAnastomosis03 medical and health sciences0302 clinical medicineIleorectal anastomosisRisk FactorsTask Performance and AnalysisColon cancer resectionHumansAnastomotic leakMedicineBlood TransfusionRisk factorcolon resectionColectomyAgedRetrospective StudiesAged 80 and overbusiness.industryAnastomosis SurgicalGastroenterologyPerioperativeMiddle Agedmedicine.diseaseSurgeryrisk factorcolon cancerElective Surgical ProceduresAnastomotic leakage030220 oncology & carcinogenesisColonic NeoplasmsFemaleClinical CompetencebusinessColorectal Disease
researchProduct

Risk factors for locally advanced cancer associated with ulcerative colitis: Results of a retrospective multicentric study in the era of biologics

2020

Abstract Background Patients affected by ulcerative colitis (UC) are more likely to develop colorectal cancer, and are often diagnosed with lymph node involvement (N+) at surgery. Aim To identify the risk factors for N+ cancer in UC patients. Methods Patients undergoing surgery from 2001 to 2018 in six European tertiary centres were included. N+ patients were compared to the control group (N−) for clinical variables. The evaluation of risk factors for N+ was assessed using univariate and multivariable logistic regression analyses. Results A total of 130 patients were included. Median duration of disease was 21 years (1–52). Forty patients (30.8%) were N+ at surgery. Eighteen (13.8%) develop…

AdultMalemedicine.medical_specialtyCancer Lymph nodes Ulcerative colitisTime FactorsAdolescentColorectal cancerDiseaseLogistic regression03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicinemedicineHumansChildLymph nodeColectomyAgedRetrospective StudiesCancerHepatologybusiness.industryLocally Advanced CancerGastroenterologyCancerOdds ratioColonoscopyMiddle Agedmedicine.diseaseUlcerative colitismedicine.anatomical_structureLogistic ModelsItalyUlcerative colitis030220 oncology & carcinogenesisMultivariate AnalysisDisease Progression030211 gastroenterology & hepatologyColitis UlcerativeFemaleLymph nodeLymph NodesbusinessColorectal Neoplasms
researchProduct